News & Media

A new survey reveals two-in-three family caregivers feel undervalued by society. The survey is a part of larger corporate caregiver commitment by Otsuka to advocate for visibility and support of family caregivers everywhere. The program was announced in November at the start of National Family Caregivers and Alzheimer’s Awareness Month. 

Otsuka Pharmaceutical Development & Commercialization, Inc. and Lundbeck Pharmaceuticals LLC announce that treatment with REXULTI^® (brexpiprazole) resulted in statistically significant and clinically meaningful improvements in adult patients with agitation associated with dementia due to Alzheimer’s disease, according to the complete results of the placebo-controlled pivotal phase 3 Study 213 (NCT03548584), published today in JAMA Neurology.

Otsuka Pharmaceutical Development & Commercialization, Inc. and Visterra Inc., today announced that the full results of a Phase 2 trial of sibeprenlimab (VIS649) for treatment of immunoglobulin A nephropathy (IgAN; Berger’s disease) have been published in the New England Journal of Medicine.¹ The topline findings will also be presented in a late-breaking poster session at the American Society of Nephrology (ASN) Kidney Week meeting in Philadelphia, PA.

This Family Health History Month, five-time Olympic gold medalist Missy Franklin is teaming up with Otsuka to shine a light on the importance of initiating family conversations about health history – particularly in those with a history of kidney disease. Through this ongoing collaboration, Missy is sharing how autosomal dominant polycystic kidney disease (ADPKD) has affected her own family. ADPKD is a rare genetic condition that causes cysts to form on the kidneys, eventually leading to a decline in kidney function and requiring a need for dialysis or a transplant.